Difference between revisions of "S100A11 (TG2)"
(New page: {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" ! {{infobox header}}| '''{{PAGENAME}}''' |- | align="center" colspan="2...) |
m |
||
| (12 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| − | | align="center" colspan="2" bgcolor="#ffffff" | [[Image: | + | | align="center" colspan="2" bgcolor="#ffffff" | [[Image:S100A11.JPG|200px|{{PAGENAME}}]] |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
| − | | | + | | S100A11 |
|- | |- | ||
| Synonyms | | Synonyms | ||
| − | | | + | | S100 calcium-binding protein A11 |
| − | + | Calgizzarin | |
|- | |- | ||
| Determination type | | Determination type | ||
| Line 22: | Line 22: | ||
|- | |- | ||
| Swissprot ID | | Swissprot ID | ||
| − | | [http://au.expasy.org/uniprot/ | + | | [http://au.expasy.org/uniprot/P31949 P31949 ] |
|- | |- | ||
| Reactive glutamines | | Reactive glutamines | ||
| − | | [[ | + | | [[TG2 reactive residues (S100A11)|Q102]] |
|- | |- | ||
| Reactive lysines | | Reactive lysines | ||
| − | | | + | | K3 |
|- | |- | ||
| Substrate sequence | | Substrate sequence | ||
| Line 39: | Line 39: | ||
|- | |- | ||
| Surface accessibility | | Surface accessibility | ||
| − | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/ | + | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1qlsA.pdf ASAView] pdf |
| + | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1qlsA.txt ASAView] txt | ||
|- | |- | ||
| Disorder prediction | | Disorder prediction | ||
| Line 48: | Line 49: | ||
|- | |- | ||
| Notes | | Notes | ||
| − | | TG2 | + | |Transamidation by TG2 transforms S100A11 into a covalently bonded homodimer |
| + | |||
| + | that acquires the capacity to signal through the p38 MAPK pathway, accelerate | ||
| + | |||
| + | chondrocyte hypertrophy and matrix catabolism. | ||
| + | |- | ||
| + | |Video | ||
| + | |{{#ev:dailymotion|1qxapT72gvd7lkY0F|300}} | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] | ||
Latest revision as of 11:55, 10 March 2015
| S100A11 (TG2) | |
|---|---|
| |
| Substrate peptide name | S100A11 |
| Synonyms | S100 calcium-binding protein A11
Calgizzarin |
| Determination type | In situ/In vitro |
| Source | Homo sapiens |
| Subcellular localization | Cytosol
Keratinocyte cornified envelope |
| Swissprot ID | P31949 |
| Reactive glutamines | Q102 |
| Reactive lysines | K3 |
| Substrate sequence | KAVPSQKRT
MASKISSPT |
| Structure | 1QLS |
| Surface accessibility | ASAView pdf
ASAView txt |
| Disorder prediction | IUPred |
| Reference | PMID:9446578 |
| Notes | Transamidation by TG2 transforms S100A11 into a covalently bonded homodimer
that acquires the capacity to signal through the p38 MAPK pathway, accelerate chondrocyte hypertrophy and matrix catabolism. |
| Video | 1qxapT72gvd7lkY0F|300}} |
